Phase 3 trials show tapinarof cream, safe effective for plaque psoriasis
Dermavant announces positive results from its two identical phase 3 trials investigating tapinarof cream 1% for treatment of plaque psoriasis in adult patients.
Dermavant announces positive results from its two identical phase 3 trials investigating tapinarof cream 1% for treatment of plaque psoriasis in adult patients.
Raj Chovatiya, MD, PhD, and Adelaide A. Hebert, MD, FAAD, comment on the newer treatments in AD, highlighting the positive impact these agents have had…
A new review highlighted JAK inhibitors’ role in vitiligo treatment, emphasizing varying benefits, facial efficacy, and potential for sustained responses.
This recap of skin cancer innovations accompanies the cover story of our May publication.
A recent survey showed education, shared decision-making, and addressing mental health concerns and financial burdens are key priorities in optimizing care.
While 84% of commercials targeted female consumers and 77% utilized celebrity influence, less than half mentioned specific ingredients in skin lightening products.
These challenges may exacerbate racial inequities in care access and quality, according to a new study.
The new research will compare eblasakimab to dupilumab and lebrikizumab.
Dermatology Times asked our readers to share what conferences they are looking forward to in the second quarter of 2024.
Earn CME credit and learn how to optimize a multimodal treatment approach for hidradenitis suppurativa.
Learn more about the in-depth topics covered in the April 2024 print issue of Dermatology Times.